Glucocorticoids decrease the numbers and activation of mast cells by inducing the transactivation receptors of AGEs

Santoro, Tassia; Azevedo, Carolina Trindade de; Silva, Patrı́cia M.R. e; Martins, Marco A.; Carvalho, Vinícius F.

doi:10.1002/jlb.3a0917-364rr

Cited by 6 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sample size, different demographic characteristics and treatment with glucocorticoids are thought to contribute to these disparities. 18 However, there are several limitations that should be acknowledged in the current study. First, the generalizability may be restricted, which may be due to the small sample size of patients.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients

et al. 2019

View full text Add to dashboard Cite

Objective To investigate the plasma galectin‐3 levels in systemic lupus erythematosus (SLE) patients and its relations with clinical and laboratory features. Methods A total of 180 subjects with 90 patients with SLE (8 male, 82 female, mean age 37.86 ± 13.98 years) and 90 healthy controls (8 male, 82 female, mean age 36.54 ± 10.89 years) were included. Plasma galectin‐3 levels were detected by enzyme‐linked immunosorbent assay (ELISA). Results There was no significant difference in age and gender distribution between SLE patients and healthy controls (both P > .05). Plasma galectin‐3 level was not significantly different between SLE patients and controls (P = .982) (P > .05). No significant difference was found regarding galectin‐3 levels between SLE with nephritis and those without nephritis (P > .05); no significant difference was found between less active SLE and more active SLE (P > .05). Galectin‐3 levels were inversely related to immune globulin M (r = −.303, P < .05), while no significant correlation between galectin‐3 levels and other quantitative laboratory parameters were observed (all P > .05). Conclusions In summary, plasma galectin‐3 level was not significantly different between SLE patients and controls (P = .982). Further studies are needed to elucidate the role of galectin‐3 in SLE.

show abstract

Section: Discussionmentioning

confidence: 94%

“…However, in our population, we could not prove these correlations. Sample size, different demographic characteristics and treatment with glucocorticoids are thought to contribute to these disparities …”

Section: Discussionmentioning

confidence: 99%

Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…( 19) Complex of glucocorticoids-glucocorticoid receptors (GC-GR) migrates to the cell nucleus to transactivation of anti-inflammatory genes and expression of genes encoding RAGE. (20) Eventhough this study reported the difference of NF-κB and RAGE expression in PROM and non-PROM subjects with infection and complications, however only limited number of samples included. Hence further study with more number of sample and by using different methods should be conducted.…”

Section: Rage Expressionmentioning

confidence: 85%

High NF-κB and RAGE Expression in Fetal Membrane of Premature Rupture of Membrane (PROM) Subject

et al. 2022

View full text Add to dashboard Cite

BACKGROUND: Premature Rupture of Membranes (PROM) is significantly linked to the infections-related maternal deaths. In the inflammatory process, the influencing stressor will stimulate the activation of Nuclear Factor Kappa B (NF-κB) and Receptor of Advanced Gyclation End product (RAGE). Yet up to date, the expression of NF-κB and RAGE in pregnant women with PROM are still rarely studied. Therefore, this study aimed to observe the differences of NF-κB and RAGE expression from PROM and non-PROM subjects.METHODS: This was a cross-sectional study involving 20 PROM subjects and 20 non-PROM subjects with infections and complications. Samples from the fetal membrane tissue of subjects were obtained and put into paraffin block preparation for the determination of NF-κB and RAGE expression. The detection of NF-κB and RAGE expression was conducted using immunohistochemical staining and observed under an upright light microscope. The expressions were later calculated using ImageJ software. RESULTS: Both NF-κB and RAGE expression were found to be higher in PROM subjects compare to the non-PROM subjects. The median of NF-κB in PROM and non-PROM subjects were 32.47±1.22 and 5.59±1.09, respectively (p=0.000). While the median of RAGE in PROM subjects was 53.58±3.46, and in non-PROM subjects was 11.64±2.49 (p=0.013).CONCLUSION: There is significant difference between NF-κB and RAGE expression in fetal membranes of PROM and non-PROM subjects. Therefore, the increased of NF-κB and RAGE expression can be used as a potential marker to detect complication of PROM.KEYWORDS: premature ruptures of membrane, non-premature ruptures of membrane, expression of NF-κB

show abstract

“…Targeting MCs is an important approach for treating IgE-mediated allergic dise MC activation can be inhibited by various clinical therapeutic agents, including antih mines, glucocorticoids, MC stabilizers, and leukotriene antibody antagonists [25][26][27][28][29] tihistamines prevent histamine molecules from binding H1 receptors, which then vents the release of histamine [26]. Although second-generation antihistamines fewer adverse secondary effects than their predecessors, they still have a sedating…”

Section: Discussionmentioning

confidence: 99%

Plant-Derived Molecule 4-Methylumbelliferone Suppresses FcεRI-Mediated Mast Cell Activation and Allergic Inflammation

et al. 2022

View full text Add to dashboard Cite

Mast cells (MCs) are an important treatment target for high-affinity IgE Fc receptor (FcεRI)-mediated allergic diseases. The plant-derived molecule 4-methylumbelliferone (4-MU) has beneficial effects in animal models of inflammation and autoimmunity diseases. The aim of this study was to examine 4-MU effects on MC activation and probe the underlying molecular mechanism(s). We sensitized rat basophilic leukemia cells (RBLs) and mouse bone marrow-derived mast cells (BMMCs) with anti-dinitrophenol (DNP) immunoglobulin (Ig)E antibodies, stimulated them with exposure to DNP-human serum albumin (HSA), and then treated stimulated cells with 4-MU. Signaling-protein expression was determined by immunoblotting. In vivo allergic responses were examined in IgE-mediated passive cutaneous anaphylaxis (PCA) and ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) mouse models. 4-MU inhibited β-hexosaminidase activity and histamine release dose-dependently in FcεRI-activated RBLs and BMMCs. Additionally, 4-MU reduced cytomorphological elongation and F-actin reorganization while down-regulating IgE/Ag-induced phosphorylation of SYK, NF-κB p65, ERK1/2, p38, and JNK. Moreover, 4-MU attenuated the PCA allergic reaction (i.e., less ear thickening and dye extravasation). Similarly, we found that 4-MU decreased body temperature, serum histamine, and IL4 secretion in OVA-challenged ASA model mice. In conclusion, 4-MU had a suppressing effect on MC activation both in vitro and in vivo and thus may represent a new strategy for treating IgE-mediated allergic conditions.

show abstract

Glucocorticoids decrease the numbers and activation of mast cells by inducing the transactivation receptors of AGEs

Cited by 6 publications

References 33 publications

Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients

Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients

High NF-κB and RAGE Expression in Fetal Membrane of Premature Rupture of Membrane (PROM) Subject

Plant-Derived Molecule 4-Methylumbelliferone Suppresses FcεRI-Mediated Mast Cell Activation and Allergic Inflammation

Contact Info

Product

Resources

About